Credit Suisse’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-4,244
| Closed | -$286K | – | 3152 |
|
|
2023
Q2 | $286K | Buy |
4,244
+1,194
| +39% | +$494K | ﹤0.01% | 3016 |
|
|
2023
Q1 | $1.42M | Buy |
3,050
+57
| +2% | +$30.2K | ﹤0.01% | 2084 |
|
|
2022
Q4 | $1.2M | Sell |
2,993
-82
| -3% | -$31.4K | ﹤0.01% | 2222 |
|
|
2022
Q3 | $1M | Buy |
3,075
+524
| +21% | +$169K | ﹤0.01% | 2340 |
|
|
2022
Q2 | $674K | Sell |
2,551
-136
| -5% | -$34.7K | ﹤0.01% | 2649 |
|
|
2022
Q1 | $807K | Buy |
2,687
+266
| +11% | +$92.7K | ﹤0.01% | 2676 |
|
|
2021
Q4 | $854K | Sell |
2,421
-359
| -13% | -$112K | ﹤0.01% | 3435 |
|
|
2021
Q3 | $710K | Sell |
2,780
-215
| -7% | -$76.2K | ﹤0.01% | 3581 |
|
|
2021
Q2 | $1.99M | Sell |
2,995
-345
| -10% | -$199K | ﹤0.01% | 2866 |
|
|
2021
Q1 | $2.9M | Sell |
3,340
-2,986
| -47% | -$3.18M | ﹤0.01% | 2543 |
|
|
2020
Q4 | $5.87M | Buy |
6,326
+2,065
| +48% | +$2.17M | ﹤0.01% | 1966 |
|
|
2020
Q3 | $4.38M | Sell |
4,261
-22,317
| -84% | -$24M | ﹤0.01% | 1879 |
|
|
2020
Q2 | $26.9M | Buy |
26,578
+4,640
| +21% | +$4.31M | 0.02% | 800 |
|
|
2020
Q1 | $19.1M | Sell |
21,938
-2,415
| -10% | -$2.4M | 0.02% | 865 |
|
|
2019
Q4 | $26.1M | Buy |
24,353
+5,024
| +26% | +$5.13M | 0.02% | 883 |
|
|
2019
Q3 | $17.9M | Sell |
19,329
-1,337
| -6% | -$1.47M | 0.02% | 985 |
|
|
2019
Q2 | $23.3M | Buy |
20,666
+272
| +1% | +$298K | 0.02% | 840 |
|
|
2019
Q1 | $27.7M | Sell |
20,394
-2,342
| -10% | -$3.18M | 0.03% | 685 |
|
|
2018
Q4 | $26.3M | Sell |
22,736
-643
| -3% | -$723K | 0.03% | 642 |
|
|
2018
Q3 | $35.5M | Sell |
23,379
-3,471
| -13% | -$5.35M | 0.03% | 568 |
|
|
2018
Q2 | $42M | Sell |
26,850
-7,951
| -23% | -$10.4M | 0.04% | 456 |
|
|
2018
Q1 | $40.2M | Buy |
34,801
+31,653
| +1,005% | +$41.7M | 0.04% | 500 |
|
|
2017
Q4 | $3.73M | Sell |
3,148
-305
| -9% | -$382K | ﹤0.01% | 1974 |
|
|
2017
Q3 | $4.64M | Buy |
3,453
+1,202
| +53% | +$1.27M | ﹤0.01% | 1816 |
|
|
2017
Q2 | $1.82M | Sell |
2,251
-3,117
| -58% | -$2.17M | ﹤0.01% | 2290 |
|
|
2017
Q1 | $3.31M | Buy |
5,368
+3,406
| +174% | +$2.07M | ﹤0.01% | 1955 |
|
|
2016
Q4 | $1.05M | Sell |
1,962
-1,059
| -35% | -$529K | ﹤0.01% | 2982 |
|
|
2016
Q3 | $1.56M | Sell |
3,021
-13,786
| -82% | -$6.49M | ﹤0.01% | 2567 |
|
|
2016
Q2 | $6.9M | Buy |
16,807
+185
| +1% | +$84.7K | 0.01% | 1416 |
|
|
2016
Q1 | $8.85M | Buy |
16,622
+10,348
| +165% | +$5.16M | 0.01% | 1176 |
|
|
2015
Q4 | $4.78M | Buy |
6,274
+1,255
| +25% | +$833K | 0.01% | 1617 |
|
|
2015
Q3 | $2.75M | Buy |
5,019
+258
| +5% | +$156K | ﹤0.01% | 2016 |
|
|
2015
Q2 | $2.8M | Buy |
4,761
+4,384
| +1,163% | +$2.55M | ﹤0.01% | 2274 |
|
|
2015
Q1 | $296K | Buy |
+377
| New | +$292K | ﹤0.01% | 3873 |
|
Other funds holding KYNB
AC
Credit Suisse's KYNB Position: Q3 2023 in Review
Credit Suisse sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 4,244 shares — an estimated $286K sold.
Credit Suisse first reported a position in KYNB in Q1 2015 and held it in 34 quarters. The position peaked at $42M in Q2 2018. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.
- Credit Suisse reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
- Credit Suisse sold 4,244 Kyntra Bio shares in Q3 2023, an estimated $286K.
- Credit Suisse first reported a position in Kyntra Bio in Q1 2015 and held it in 34 quarters.
- Credit Suisse's Kyntra Bio position peaked at $42M in Q2 2018.
- 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.
Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.